Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the ...
Jul 12, 2016 ... Among the partners' goals: planning a double-blind, placebo-controlled clinical trial of nilotinib, which MJFF hopes can begin in 2017.
Sep 15, 2016 ... Nilotinib: learn about side effects, dosage, special precautions, and more on MedlinePlus.
TASIGNA® (nilotinib) is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ ...
Learn how TASIGNA® (nilotinib) can be prescribed to treat Ph+ positive chronic myeloid leukemia. See full Safety & Prescribing Info and BOXED WARNING.
Jul 3, 2013 ... Information from the FDA about the approval of nilotinib and the clinical trials that led to the approval.
Find out what nilotinib is, how you have it and other important information about taking nilotinib.
Nilotinib (Tasigna) targeted therapy side effects, how it's given, how it works, precautions and self care tips for treatment of chronic myeloid leukemia.
Mar 6, 2017 ... Nilotinib drug substance, a monohydrate monohydrochloride, is a white to slightly yellowish to slightly greenish yellow powder with the ...